Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes

Ovarian Tumor Tissue Analysis (OTTA) Consortium; Nicola S Meagher; Kylie L Gorringe; Matthew J Wakefield; Adelyn Bolithon; Chi Nam Ignatius Pang; Derek S Chiu; Michael S Anglesio; Kylie-Ann Mallitt; Jennifer A Doherty; Holly R Harris; Joellen M Schildkraut; Andrew Berchuck; Kara L Cushing-Haugen; Ksenia Chezar; Angela Chou; Adeline Tan; Jennifer Alsop; Ellen Barlow; Matthias W Beckmann; Jessica Boros; David D Bowtell; Alison H Brand; James D Brenton; Ian Campbell; Dane Cheasley; Joshua Cohen; Cezary Cybulski; Esther Elishaev; Ramona Erber; Rhonda Farrell; Anna Fischer; Zhuxuan Fu; Blake Gilks; Anthony J Gill; Charlie Gourley; Marcel Grube; Paul Harnett; Arndt Hartmann; Anusha Hettiaratchi; Claus K Høgdall; Tomasz Huzarski; Anna Jakubowska; Mercedes Jimenez-Linan; Catherine J Kennedy; Byoung-Gie Kim; Jae-Weon Kim; Jae-Hoon Kim; Kayla Klett; Jennifer Koziak; Tiffany Lai; Angela Laslavic; Jenny Lester; Yee Leung; Na Li; Winston Liauw; Belle W X Lim; Anna Linder; Jan Lubinski; Sakshi Mahale; Constantina Mateoiu; Simone McInerny; Janusz Menkiszak; Parham Minoo; Suzana Mittelstadt; David Morris; Sandra Orsulic; Sang Yoon Park; Celeste Leigh Pearce; John V Pearson; Malcolm C Pike; Carmel M Quinn; Ganendra Raj Mohan; JianYu Rao; Marjorie J Riggan; Matthias Ruebner; Stuart Salfinger; Clare L Scott; Mitul Shah; Helen Steed; Colin J R Stewart; Deepak Subramanian; Soseul Sung; Katrina Tang; Paul Timpson; Robyn L Ward; Rebekka Wiedenhoefer; Heather Thorne; Paul A Cohen; Philip Crowe; Peter A Fasching; Jacek Gronwald; Nicholas J Hawkins; Estrid Høgdall; David G Huntsman; Paul A James; Beth Y Karlan; Linda E Kelemen; Stefan Kommoss; Gottfried E Konecny; Francesmary Modugno; Sue K Park; Annette Staebler; Karin Sundfeldt; Anna H Wu; Aline Talhouk; Paul D P Pharoah; Lyndal Anderson; Anna DeFazio; Martin Köbel; Michael L Friedlander

doi:10.1158/1078-0432.CCR-22-1206

Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes

Ovarian Tumor Tissue Analysis (OTTA) Consortium, Nicola S Meagher, Kylie L Gorringe, Matthew J Wakefield, Adelyn Bolithon, Chi Nam Ignatius Pang, Derek S Chiu, Michael S Anglesio, Kylie-Ann Mallitt, Jennifer A Doherty, Holly R Harris, Joellen M Schildkraut, Andrew Berchuck, Kara L Cushing-Haugen, Ksenia Chezar, Angela Chou, Adeline Tan, Jennifer Alsop, Ellen Barlow, Matthias W BeckmannJessica Boros, David D Bowtell, Alison H Brand, James D Brenton, Ian Campbell, Dane Cheasley, Joshua Cohen, Cezary Cybulski, Esther Elishaev, Ramona Erber, Rhonda Farrell, Anna Fischer, Zhuxuan Fu, Blake Gilks, Anthony J Gill, Charlie Gourley, Marcel Grube, Paul Harnett, Arndt Hartmann, Anusha Hettiaratchi, Claus K Høgdall, Tomasz Huzarski, Anna Jakubowska, Mercedes Jimenez-Linan, Catherine J Kennedy, Byoung-Gie Kim, Jae-Weon Kim, Jae-Hoon Kim, Kayla Klett, Jennifer Koziak, Tiffany Lai, Angela Laslavic, Jenny Lester, Yee Leung, Na Li, Winston Liauw, Belle W X Lim, Anna Linder, Jan Lubinski, Sakshi Mahale, Constantina Mateoiu, Simone McInerny, Janusz Menkiszak, Parham Minoo, Suzana Mittelstadt, David Morris, Sandra Orsulic, Sang Yoon Park, Celeste Leigh Pearce, John V Pearson, Malcolm C Pike, Carmel M Quinn, Ganendra Raj Mohan, JianYu Rao, Marjorie J Riggan, Matthias Ruebner, Stuart Salfinger, Clare L Scott, Mitul Shah, Helen Steed, Colin J R Stewart, Deepak Subramanian, Soseul Sung, Katrina Tang, Paul Timpson, Robyn L Ward, Rebekka Wiedenhoefer, Heather Thorne, Paul A Cohen, Philip Crowe, Peter A Fasching, Jacek Gronwald, Nicholas J Hawkins, Estrid Høgdall, David G Huntsman, Paul A James, Beth Y Karlan, Linda E Kelemen, Stefan Kommoss, Gottfried E Konecny, Francesmary Modugno, Sue K Park, Annette Staebler, Karin Sundfeldt, Anna H Wu, Aline Talhouk, Paul D P Pharoah, Lyndal Anderson, Anna DeFazio, Martin Köbel, Michael L Friedlander

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

PURPOSE: Advanced stage MOC have poor chemotherapy response and prognosis and lack biomarkers to aid Stage I adjuvant treatment. Differentiating primary mucinous ovarian carcinoma (MOC) from gastrointestinal (GI) metastases to the ovary is also challenging due to phenotypic similarities. Clinicopathological and gene expression data were analysed to identify prognostic and diagnostic features.

EXPERIMENTAL DESIGN: Discovery analyses selected 19 genes with prognostic/diagnostic potential. Validation was performed through the Ovarian Tumor Tissue Analysis consortium and GI cancer biobanks comprising 604 patients with MOC (n=333), mucinous borderline ovarian tumors (MBOT, n=151), upper GI (n=65), and lower GI tumors (n=55).

RESULTS: Infiltrative pattern of invasion was associated with decreased overall survival (OS) within 2-years from diagnosis, compared with expansile pattern in Stage I MOC (hazard ratio HR 2.77 (1.04-7.41, p=0.042). Increased expression of THBS2 and TAGLN were associated with shorter OS in MOC patients, (HR 1.25 (95% CI 1.04-1.51, p=0.016)) and (1.21 (1.01-1.45, p=0.043)) respectively. ERBB2 (HER2)-amplification or high mRNA expression was evident in 64/243 (26%) of MOCs, but only 8/243 (3%) were also infiltrative (4/39, 10%) or Stage III/IV (4/31, 13%).

CONCLUSIONS: An infiltrative growth pattern infers poor prognosis within 2-years from diagnosis and may help select Stage I patients for adjuvant therapy. High expression of THBS2 and TAGLN in MOC confer an adverse prognosis and is upregulated in the infiltrative subtype which warrants further investigation. Anti-HER2 therapy should be investigated in a subset of patients. MOC samples clustered with upper GI, yet markers to differentiate these entities remain elusive, suggesting similar underlying biology and shared treatment strategies.

Original language	English
Pages (from-to)	5383-5395
Number of pages	13
Journal	Clinical cancer research : an official journal of the American Association for Cancer Research
Volume	28
Issue number	24
Early online date	12 Oct 2022
DOIs	https://doi.org/10.1158/1078-0432.CCR-22-1206
Publication status	Published - 15 Dec 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1078-0432.CCR-22-1206Licence: CC BY

Cite this

Ovarian Tumor Tissue Analysis (OTTA) Consortium, Meagher, N. S., Gorringe, K. L., Wakefield, M. J., Bolithon, A., Pang, C. N. I., Chiu, D. S., Anglesio, M. S., Mallitt, K.-A., Doherty, J. A., Harris, H. R., Schildkraut, J. M., Berchuck, A., Cushing-Haugen, K. L., Chezar, K., Chou, A., Tan, A., Alsop, J., Barlow, E., ... Friedlander, M. L. (2022). Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(24), 5383-5395. https://doi.org/10.1158/1078-0432.CCR-22-1206

Ovarian Tumor Tissue Analysis (OTTA) Consortium ; Meagher, Nicola S ; Gorringe, Kylie L et al. / Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes. In: Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 ; Vol. 28, No. 24. pp. 5383-5395.

@article{e339a7d1980c447ebe16088e97a8b51b,

title = "Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes",

abstract = "PURPOSE: Advanced stage MOC have poor chemotherapy response and prognosis and lack biomarkers to aid Stage I adjuvant treatment. Differentiating primary mucinous ovarian carcinoma (MOC) from gastrointestinal (GI) metastases to the ovary is also challenging due to phenotypic similarities. Clinicopathological and gene expression data were analysed to identify prognostic and diagnostic features.EXPERIMENTAL DESIGN: Discovery analyses selected 19 genes with prognostic/diagnostic potential. Validation was performed through the Ovarian Tumor Tissue Analysis consortium and GI cancer biobanks comprising 604 patients with MOC (n=333), mucinous borderline ovarian tumors (MBOT, n=151), upper GI (n=65), and lower GI tumors (n=55).RESULTS: Infiltrative pattern of invasion was associated with decreased overall survival (OS) within 2-years from diagnosis, compared with expansile pattern in Stage I MOC (hazard ratio HR 2.77 (1.04-7.41, p=0.042). Increased expression of THBS2 and TAGLN were associated with shorter OS in MOC patients, (HR 1.25 (95% CI 1.04-1.51, p=0.016)) and (1.21 (1.01-1.45, p=0.043)) respectively. ERBB2 (HER2)-amplification or high mRNA expression was evident in 64/243 (26%) of MOCs, but only 8/243 (3%) were also infiltrative (4/39, 10%) or Stage III/IV (4/31, 13%).CONCLUSIONS: An infiltrative growth pattern infers poor prognosis within 2-years from diagnosis and may help select Stage I patients for adjuvant therapy. High expression of THBS2 and TAGLN in MOC confer an adverse prognosis and is upregulated in the infiltrative subtype which warrants further investigation. Anti-HER2 therapy should be investigated in a subset of patients. MOC samples clustered with upper GI, yet markers to differentiate these entities remain elusive, suggesting similar underlying biology and shared treatment strategies.",

author = "{Ovarian Tumor Tissue Analysis (OTTA) Consortium} and Meagher, {Nicola S} and Gorringe, {Kylie L} and Wakefield, {Matthew J} and Adelyn Bolithon and Pang, {Chi Nam Ignatius} and Chiu, {Derek S} and Anglesio, {Michael S} and Kylie-Ann Mallitt and Doherty, {Jennifer A} and Harris, {Holly R} and Schildkraut, {Joellen M} and Andrew Berchuck and Cushing-Haugen, {Kara L} and Ksenia Chezar and Angela Chou and Adeline Tan and Jennifer Alsop and Ellen Barlow and Beckmann, {Matthias W} and Jessica Boros and Bowtell, {David D} and Brand, {Alison H} and Brenton, {James D} and Ian Campbell and Dane Cheasley and Joshua Cohen and Cezary Cybulski and Esther Elishaev and Ramona Erber and Rhonda Farrell and Anna Fischer and Zhuxuan Fu and Blake Gilks and Gill, {Anthony J} and Charlie Gourley and Marcel Grube and Paul Harnett and Arndt Hartmann and Anusha Hettiaratchi and H{\o}gdall, {Claus K} and Tomasz Huzarski and Anna Jakubowska and Mercedes Jimenez-Linan and Kennedy, {Catherine J} and Byoung-Gie Kim and Jae-Weon Kim and Jae-Hoon Kim and Kayla Klett and Jennifer Koziak and Tiffany Lai and Angela Laslavic and Jenny Lester and Yee Leung and Na Li and Winston Liauw and Lim, {Belle W X} and Anna Linder and Jan Lubinski and Sakshi Mahale and Constantina Mateoiu and Simone McInerny and Janusz Menkiszak and Parham Minoo and Suzana Mittelstadt and David Morris and Sandra Orsulic and Park, {Sang Yoon} and Pearce, {Celeste Leigh} and Pearson, {John V} and Pike, {Malcolm C} and Quinn, {Carmel M} and Mohan, {Ganendra Raj} and JianYu Rao and Riggan, {Marjorie J} and Matthias Ruebner and Stuart Salfinger and Scott, {Clare L} and Mitul Shah and Helen Steed and Stewart, {Colin J R} and Deepak Subramanian and Soseul Sung and Katrina Tang and Paul Timpson and Ward, {Robyn L} and Rebekka Wiedenhoefer and Heather Thorne and Cohen, {Paul A} and Philip Crowe and Fasching, {Peter A} and Jacek Gronwald and Hawkins, {Nicholas J} and Estrid H{\o}gdall and Huntsman, {David G} and James, {Paul A} and Karlan, {Beth Y} and Kelemen, {Linda E} and Stefan Kommoss and Konecny, {Gottfried E} and Francesmary Modugno and Park, {Sue K} and Annette Staebler and Karin Sundfeldt and Wu, {Anna H} and Aline Talhouk and Pharoah, {Paul D P} and Lyndal Anderson and Anna DeFazio and Martin K{\"o}bel and Friedlander, {Michael L} and Ramus, {Susan J}",

year = "2022",

month = dec,

day = "15",

doi = "10.1158/1078-0432.CCR-22-1206",

language = "English",

volume = "28",

pages = "5383--5395",

journal = "Clinical cancer research : an official journal of the American Association for Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "24",

}

Ovarian Tumor Tissue Analysis (OTTA) Consortium, Meagher, NS, Gorringe, KL, Wakefield, MJ, Bolithon, A, Pang, CNI, Chiu, DS, Anglesio, MS, Mallitt, K-A, Doherty, JA, Harris, HR, Schildkraut, JM, Berchuck, A, Cushing-Haugen, KL, Chezar, K, Chou, A, Tan, A, Alsop, J, Barlow, E, Beckmann, MW, Boros, J, Bowtell, DD, Brand, AH, Brenton, JD, Campbell, I, Cheasley, D, Cohen, J, Cybulski, C, Elishaev, E, Erber, R, Farrell, R, Fischer, A, Fu, Z, Gilks, B, Gill, AJ, Gourley, C, Grube, M, Harnett, P, Hartmann, A, Hettiaratchi, A, Høgdall, CK, Huzarski, T, Jakubowska, A, Jimenez-Linan, M, Kennedy, CJ, Kim, B-G, Kim, J-W, Kim, J-H, Klett, K, Koziak, J, Lai, T, Laslavic, A, Lester, J, Leung, Y, Li, N, Liauw, W, Lim, BWX, Linder, A, Lubinski, J, Mahale, S, Mateoiu, C, McInerny, S, Menkiszak, J, Minoo, P, Mittelstadt, S, Morris, D, Orsulic, S, Park, SY, Pearce, CL, Pearson, JV, Pike, MC, Quinn, CM, Mohan, GR, Rao, J, Riggan, MJ, Ruebner, M, Salfinger, S, Scott, CL, Shah, M, Steed, H, Stewart, CJR, Subramanian, D, Sung, S, Tang, K, Timpson, P, Ward, RL, Wiedenhoefer, R, Thorne, H, Cohen, PA, Crowe, P, Fasching, PA, Gronwald, J, Hawkins, NJ, Høgdall, E, Huntsman, DG, James, PA, Karlan, BY, Kelemen, LE, Kommoss, S, Konecny, GE, Modugno, F, Park, SK, Staebler, A, Sundfeldt, K, Wu, AH, Talhouk, A, Pharoah, PDP, Anderson, L, DeFazio, A, Köbel, M & Friedlander, ML 2022, 'Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 28, no. 24, pp. 5383-5395. https://doi.org/10.1158/1078-0432.CCR-22-1206

Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes. / Ovarian Tumor Tissue Analysis (OTTA) Consortium; Meagher, Nicola S; Gorringe, Kylie L et al.
In: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, No. 24, 15.12.2022, p. 5383-5395.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes

AU - Ovarian Tumor Tissue Analysis (OTTA) Consortium

AU - Meagher, Nicola S

AU - Gorringe, Kylie L

AU - Wakefield, Matthew J

AU - Bolithon, Adelyn

AU - Pang, Chi Nam Ignatius

AU - Chiu, Derek S

AU - Anglesio, Michael S

AU - Mallitt, Kylie-Ann

AU - Doherty, Jennifer A

AU - Harris, Holly R

AU - Schildkraut, Joellen M

AU - Berchuck, Andrew

AU - Cushing-Haugen, Kara L

AU - Chezar, Ksenia

AU - Chou, Angela

AU - Tan, Adeline

AU - Alsop, Jennifer

AU - Barlow, Ellen

AU - Beckmann, Matthias W

AU - Boros, Jessica

AU - Bowtell, David D

AU - Brand, Alison H

AU - Brenton, James D

AU - Campbell, Ian

AU - Cheasley, Dane

AU - Cohen, Joshua

AU - Cybulski, Cezary

AU - Elishaev, Esther

AU - Erber, Ramona

AU - Farrell, Rhonda

AU - Fischer, Anna

AU - Fu, Zhuxuan

AU - Gilks, Blake

AU - Gill, Anthony J

AU - Gourley, Charlie

AU - Grube, Marcel

AU - Harnett, Paul

AU - Hartmann, Arndt

AU - Hettiaratchi, Anusha

AU - Høgdall, Claus K

AU - Huzarski, Tomasz

AU - Jakubowska, Anna

AU - Jimenez-Linan, Mercedes

AU - Kennedy, Catherine J

AU - Kim, Byoung-Gie

AU - Kim, Jae-Weon

AU - Kim, Jae-Hoon

AU - Klett, Kayla

AU - Koziak, Jennifer

AU - Lai, Tiffany

AU - Laslavic, Angela

AU - Lester, Jenny

AU - Leung, Yee

AU - Li, Na

AU - Liauw, Winston

AU - Lim, Belle W X

AU - Linder, Anna

AU - Lubinski, Jan

AU - Mahale, Sakshi

AU - Mateoiu, Constantina

AU - McInerny, Simone

AU - Menkiszak, Janusz

AU - Minoo, Parham

AU - Mittelstadt, Suzana

AU - Morris, David

AU - Orsulic, Sandra

AU - Park, Sang Yoon

AU - Pearce, Celeste Leigh

AU - Pearson, John V

AU - Pike, Malcolm C

AU - Quinn, Carmel M

AU - Mohan, Ganendra Raj

AU - Rao, JianYu

AU - Riggan, Marjorie J

AU - Ruebner, Matthias

AU - Salfinger, Stuart

AU - Scott, Clare L

AU - Shah, Mitul

AU - Steed, Helen

AU - Stewart, Colin J R

AU - Subramanian, Deepak

AU - Sung, Soseul

AU - Tang, Katrina

AU - Timpson, Paul

AU - Ward, Robyn L

AU - Wiedenhoefer, Rebekka

AU - Thorne, Heather

AU - Cohen, Paul A

AU - Crowe, Philip

AU - Fasching, Peter A

AU - Gronwald, Jacek

AU - Hawkins, Nicholas J

AU - Høgdall, Estrid

AU - Huntsman, David G

AU - James, Paul A

AU - Karlan, Beth Y

AU - Kelemen, Linda E

AU - Kommoss, Stefan

AU - Konecny, Gottfried E

AU - Modugno, Francesmary

AU - Park, Sue K

AU - Staebler, Annette

AU - Sundfeldt, Karin

AU - Wu, Anna H

AU - Talhouk, Aline

AU - Pharoah, Paul D P

AU - Anderson, Lyndal

AU - DeFazio, Anna

AU - Köbel, Martin

AU - Friedlander, Michael L

AU - Ramus, Susan J

PY - 2022/12/15

Y1 - 2022/12/15

N2 - PURPOSE: Advanced stage MOC have poor chemotherapy response and prognosis and lack biomarkers to aid Stage I adjuvant treatment. Differentiating primary mucinous ovarian carcinoma (MOC) from gastrointestinal (GI) metastases to the ovary is also challenging due to phenotypic similarities. Clinicopathological and gene expression data were analysed to identify prognostic and diagnostic features.EXPERIMENTAL DESIGN: Discovery analyses selected 19 genes with prognostic/diagnostic potential. Validation was performed through the Ovarian Tumor Tissue Analysis consortium and GI cancer biobanks comprising 604 patients with MOC (n=333), mucinous borderline ovarian tumors (MBOT, n=151), upper GI (n=65), and lower GI tumors (n=55).RESULTS: Infiltrative pattern of invasion was associated with decreased overall survival (OS) within 2-years from diagnosis, compared with expansile pattern in Stage I MOC (hazard ratio HR 2.77 (1.04-7.41, p=0.042). Increased expression of THBS2 and TAGLN were associated with shorter OS in MOC patients, (HR 1.25 (95% CI 1.04-1.51, p=0.016)) and (1.21 (1.01-1.45, p=0.043)) respectively. ERBB2 (HER2)-amplification or high mRNA expression was evident in 64/243 (26%) of MOCs, but only 8/243 (3%) were also infiltrative (4/39, 10%) or Stage III/IV (4/31, 13%).CONCLUSIONS: An infiltrative growth pattern infers poor prognosis within 2-years from diagnosis and may help select Stage I patients for adjuvant therapy. High expression of THBS2 and TAGLN in MOC confer an adverse prognosis and is upregulated in the infiltrative subtype which warrants further investigation. Anti-HER2 therapy should be investigated in a subset of patients. MOC samples clustered with upper GI, yet markers to differentiate these entities remain elusive, suggesting similar underlying biology and shared treatment strategies.

AB - PURPOSE: Advanced stage MOC have poor chemotherapy response and prognosis and lack biomarkers to aid Stage I adjuvant treatment. Differentiating primary mucinous ovarian carcinoma (MOC) from gastrointestinal (GI) metastases to the ovary is also challenging due to phenotypic similarities. Clinicopathological and gene expression data were analysed to identify prognostic and diagnostic features.EXPERIMENTAL DESIGN: Discovery analyses selected 19 genes with prognostic/diagnostic potential. Validation was performed through the Ovarian Tumor Tissue Analysis consortium and GI cancer biobanks comprising 604 patients with MOC (n=333), mucinous borderline ovarian tumors (MBOT, n=151), upper GI (n=65), and lower GI tumors (n=55).RESULTS: Infiltrative pattern of invasion was associated with decreased overall survival (OS) within 2-years from diagnosis, compared with expansile pattern in Stage I MOC (hazard ratio HR 2.77 (1.04-7.41, p=0.042). Increased expression of THBS2 and TAGLN were associated with shorter OS in MOC patients, (HR 1.25 (95% CI 1.04-1.51, p=0.016)) and (1.21 (1.01-1.45, p=0.043)) respectively. ERBB2 (HER2)-amplification or high mRNA expression was evident in 64/243 (26%) of MOCs, but only 8/243 (3%) were also infiltrative (4/39, 10%) or Stage III/IV (4/31, 13%).CONCLUSIONS: An infiltrative growth pattern infers poor prognosis within 2-years from diagnosis and may help select Stage I patients for adjuvant therapy. High expression of THBS2 and TAGLN in MOC confer an adverse prognosis and is upregulated in the infiltrative subtype which warrants further investigation. Anti-HER2 therapy should be investigated in a subset of patients. MOC samples clustered with upper GI, yet markers to differentiate these entities remain elusive, suggesting similar underlying biology and shared treatment strategies.

UR - http://www.scopus.com/inward/record.url?scp=85141531275&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-22-1206

DO - 10.1158/1078-0432.CCR-22-1206

M3 - Article

C2 - 36222710

SN - 1078-0432

VL - 28

SP - 5383

EP - 5395

JO - Clinical cancer research : an official journal of the American Association for Cancer Research

JF - Clinical cancer research : an official journal of the American Association for Cancer Research

IS - 24

ER -

Ovarian Tumor Tissue Analysis (OTTA) Consortium, Meagher NS, Gorringe KL, Wakefield MJ, Bolithon A, Pang CNI et al. Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Dec 15;28(24):5383-5395. Epub 2022 Oct 12. doi: 10.1158/1078-0432.CCR-22-1206

Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this